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Background: The variable clinical and histopathological manifestations of immu-
noglobulin A nephropathy (IgAN) make it difﬁcult to predict disease progression.
A recent study showed that hyperuricemia, a condition common in hypertension
and vascular disease, may contribute to renal dysfunction and histological changes
including renal arteriosclerosis, tubular atrophy, and interstitial ﬁbrosis. Herein,
we investigated the clinical signiﬁcance of uric acid level at the time of biopsy, as a
marker of IgAN progression.
Methods: We included 193 patients with biopsy-proven IgAN. Renal disease
progression was deﬁned as serum creatinine elevation above 1.2 mg/dL or over
20% elevation from baseline. Hyperuricemia was deﬁned as a serum uric acid level
Z7.3 mg/dL in men and Z5.3 mg/dL in women, which were 1 standard deviation
above the mean value in the normal subjects.
Results: The hyperuricemia group (n¼50) had higher blood pressure, body mass
index, and serum creatinine, and a greater amount of proteinuria and a lower
glomerular ﬁltration rate than the nonhyperuricemia group (n¼143). Hyperur-
icemia increased the risk of IgAN progression (odds ratio, 4.53; 95% conﬁdence
interval, 1.31–15.66). The disease progression group (n¼26) had a greater
frequency of hyperuricemia, hypertension, and nephrotic range proteinuria than
the nonprogression group (n¼119). The renal survival analysis showed that the
hyperuricemia group had a higher rate of IgAN disease progression.
Conclusion: Hyperuricemia at the time of diagnosis is an important marker for
IgAN progression.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
y, Department of Internal
Hospital 23-20Introduction
Immunoglobulin A nephropathy (IgAN) is the most com-
mon chronic glomerulonephritis worldwide [1]. The course of
IgAN is variable, with 10%–20% of patients developing end-
stage renal disease in the ﬁrst 10 years after the diagnosis [2].
Early detection and intervention for adjustable risk factors
may reduce or slow the rate of progression of chronic renalublished by Elsevier. This is an open access article under the CC BY-NC-
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renal insufﬁciency, hypertension, and proteinuria at the time
of diagnosis [3]. Recent studies suggest that uric acid is
associated with IgAN progression [4,5].
High serum uric acid levels may reﬂect a decrease in
renal blood ﬂow and early hypertensive nephrosclerosis. Serum
uric acid may play a pathologic role in renal vasoconstriction,
endothelial dysfunction, inﬂammatory response, oxidative
stress, and the disturbances in autoregulation that occur with
acute renal failure [6]. Recently, the reassessment of the role of
hyperuricemia suggests its direct pathogenicity as well as a
marker for other associated risk factors [7–10].
The aim of the present study was to evaluate the associa-
tion between uric acid levels at the time of IgAN diagnosis and
renal prognosis in patients with biopsy-proven IgAN.Methods
Study population and study design
This study included all the patients with IgAN diagnosed at
the Soonchunhyang University Cheonan Hospital between
January 1999 and December 2005. A renal biopsy specimen
was considered adequate if it contained 4 or more glomeruli.
IgAN was deﬁned as glomerulonephritis with predominant IgA
deposition in the glomerular mesangium. 193 patients (103
men [53.4%] and 90 women [46.6%]) fulﬁlled this criterion. The
median age at the time of renal biopsy was 34 years (range 14–
71). The Hospital’s Investigational Review Board approved this193 patients en
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Figure 1. Study design astudy and all participants provided written informed consent.
The clinical data were collected by retrospective review of the
medical record system of the Hospital.
Clinical data
Systemic lupus erythematosus, liver cirrhosis, or the typi-
cal picture of Henoch–Scho¨nlein purpura was not observed
in our cases. Of the 193 patients (hyperuricemia, n¼50;
nonhyperuricemia, n¼143) enrolled in the study at the time
of renal biopsy, 48 (24.9%) were excluded: 33 did not attend
follow-up visits, 13 had incomplete laboratory data, and
2 were followed for o1 year. Thus, 145 patients were
included in the analysis (hyperuricemia, n¼37; nonhyperur-
icemia, n¼108; Fig. 1). The median follow-up time after renal
biopsy was 5.8 years (range 1.2–10). All the clinical para-
meters were measured at the time of renal biopsy. Data on
medication, diabetes mellitus, body mass index (BMI), blood
pressure (BP), 24-h urinary protein excretion, serum lipid
proﬁle, and serum uric acid level at the time of renal biopsy
were recorded. The deﬁnition of hypertension was the use of
antihypertensive medication at the time of renal biopsy or a
systolic BP 4140 mmHg and/or diastolic BP 490 mmHg as
measured during hospitalization for renal biopsy. By this
deﬁnition, 40 patients had hypertension. Nine patients had
diabetes mellitus (non–insulin-dependent diabetes mellitus).
The pathology grading system was determined according to
Lee [11]. Hypercholesterolemia and hypertriglyceridemia
were deﬁned as serum cholesterol 4250 mg/dL and serum
triglyceride 4200 mg/dL, respectively.rolled  
Non-hyperuricemia group  
at the time of biopsy (n = 143) 
35 patients excluded 
- 27 no follow up visit 
- 6 incomplete data collection 
- 2 follow-up loss less than 1 year 
Non-hyperuricemia group 
at the end of the study (n = 108)
Progression
(n = 12) 
Non-progression 
(n = 96) 
nd renal outcomes.
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From January 2002 to May 2007, the 7,354 people who
presented for a medical check-up at the health promotion
center of Soonchunhyang University Cheonan Hospital were
enrolled as a control group to deﬁne hyperuricemia. Of them,
1,109 cases with hematuria, proteinuria, hypertension, or
diabetes mellitus were excluded. The uric acid level
(mean7SD) of this control group (n = 6,245) was
5.2471.43 mg/dL, with men (n¼3,509) having mean values
of 6.0271.27 mg/dL and women (n¼2,736), 4.3270.97 mg/
dL. Hyperuricemia was deﬁned as a serum uric acid level
Z7.3 mg/dL in men or Z5.3 mg/dL in women. These cut off
points are 1 standard deviation above the mean values in the
normal control subjects.Deﬁnition of IgAN progression
The initial measurement of serum creatinine was
obtained at the time of the renal biopsy. The serum creati-
nine measured at the last follow-up visit was used when
deﬁning IgAN progression. Serum creatinine values were
considered normal if they were r1.2 mg/dL. IgAN progres-
sion during follow-up was deﬁned as elevation of the serum
creatinine above the normal level or a 420% increase from
the baseline level (in patients who had elevated creatinine at
the time of biopsy). Serum creatinine values were measured
at approximately 1-year intervals during the follow-up.
These values were used when studying the time interval in
years until impaired renal function developed; this interval
was used in renal survival curve analysis in relation to
hyperuricemia. Urine protein excretion was measured in a
24-h urine collection. Proteinuria and nephrotic range pro-
teinuria were deﬁned as protein excretion Z1 g/day and
Z3.5 g/day, respectively.Table 1. Clinical characteristics of IgAN patients with or without hype
Hyperuricemian (n ¼ 50)
Sex, men, n (%) 25 (50%)
Age 34.94712.14
DM, n (%) 2 (4.0%)
Hypertension n (%) 16 (32.0%)
Systolic BP (mmHg) 127.60713.33
Diastolic BP (mmHg) 81.2079.18
BMI 25.3874.16
Albumin (g/dL) 3.8470.64
Blood urea nitrogen (mg/dL) 19.84713.07
Creatinine (mg/dL) 1.4671.27
Initial GFR (ml/min/1.73 m2) 69.59729.27
Uric acid (mg/dL) 7.6671.66
Cholesterol (mg/dL) 174.53796.96
Triglyceride (mg/dL) 204.98748.97
Hypercholesterolemia, n (%) 10 (20.0%)
Hypertriglyceridemia, n (%) 27 (54%)
24-h protein (mg/d) 158571643
Proteinuria (41.0 g/d), n (%) 28 (56.0%)
Proteinuria (43.5 g/d), n (%) 7 (14.0%)
Pathologic grade IV/Vz, n (%) 14 (28%)
n Serum uric acid levels,Z7.3 mg/dL in men or Z5.3 mg/dL in women.
y By Chi-square test.
z The pathologic grading system was determined according to Lee [11].
SI conversion factors: values were multiplied by 10 to convert albumin to
mmol/L; values were multiplied by 88.4 to convert creatinine to mmol/L; v
were multiplied by 0.02586 to convert cholesterol to mmol/L; and values w
BMI, body mass index; BP, blood pressure; DM, diabetes mellitus; GFR, gloStatistical methods
Data are presented as the mean (SD) values for continuous
variables and as frequency (percentage) for categorical variables.
A P value o0.05 was considered statistically signiﬁcant.
The statistical analysis was performed with the SPSS program
for Windows (version 14.0; SPSS, Inc., Chicago, Illinois, USA).
The inter-group differences were compared with the Student
t test for continuous variables and the Chi-square test for
categorical variables. Survival analysis for stable renal func-
tion related to hyperuricemia was carried out by the Kaplan–
Meier survival curve. Differences between survival curves
were tested by the log-rank test. Multiple logistic regression
analysis was used to determine the factors affecting IgAN
progression. The strength of the association between uric acid
and IgAN progression was expressed as odds ratio (OR).Results
Hyperuricemia and clinical risk factors at the time
of renal biopsy
The hyperuricemia group had higher systolic and diastolic
BP, BMI, serum creatinine, serum cholesterol, and triglycer-
ides (Table 1). In addition, patients with hyperuricemia
showed class IV and V renal lesions and lower glomerular
ﬁltration rate (GFR; o60 mL/min/1.73 m2) and proteinuria
more frequently than patients without hyperuricemia at the
time of renal biopsy (Table 1). Univariate analysis between
GFR and hyperuricemia showed that hyperuricemia increased
the risk of GFRo60 mL/min/1.73 m2 by 6.14-fold [95% con-
ﬁdence interval (CI) 2.69–14.03]. After adjustments for age,
gender, hypertension, BMI, hypercholesterolemia, and hyper-
triglyceridemia, the risk was still increased by 4.20-fold (95%
CI 1.53–11.52; Table 2).ruricemia at the time of renal biopsy
Nonhyperuricemia (n ¼ 143) P
78 (54.5%) 0.6y
33.34713.69 0.5
8 (5.6%) 1.000y
24 (16.8%) 0.03y
120.94715.63 0.008
76.75710.35 0.008
22.7672.94 0.000
3.8270.66 0.8
13.5574.41 o0.001
0.9870.27 o0.001
89.90723.14 o0.001
4.9271.23 o0.001
119.86764.90 o0.001
175.15751.43 o0.001
9 (6.3%) 0.010y
26 (18.2%) o0.001y
138672679 0.6
45 (31.5%) 0.004y
13 (9.2%) 0.4y
7 (4.9%) o0.001y
g/L; values were multiplied by 0.357 to convert blood urea nitrogen to
alues were multiplied by 59.48 to convert uric acid to mmol/L; values
ere multiplied by 0.01129 to convert triglyceride to mmol/L.
merular ﬁltration rate.
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Among 145 patients, 121 (81%) had normal serum creatinine
levels and 24 (19%) had elevated levels at the time of the renal
biopsy. IgAN progression was found in 8 of the 24 patients
(33.3%) with elevated serum creatinine at biopsy. Patients with
progression had initially higher levels of systolic and diastolic BP,
uric acid, and triglycerides, and a higher frequency of proteinuria
and nephrotic range proteinuria (Table 3). The serum creatinine
was normalized in 9 of these 24 (37.5%) patients, but remained
elevated without a further increase over 20% in 7 (29.1%). Thus,
26 (17.9%) of the study patients had IgAN progression according
to the deﬁnition in this study. In 24 of these 26 patients, the last
measured serum creatinine was 41.5 mg/dL. The serum crea-
tinine increased from 0.8 to 1.3 mg/dL and from 0.9 to 1.4 mg/
dL in 2 of the 26 patients. End stage renal disease (requiring
dialysis) developed in 11 patients (5.5%).
Association between serum hyperuricemia and
IgAN progression
The serum uric acid level at the time of renal biopsy was
signiﬁcantly higher in patients who progressed than those who
did not (Table 3) and hyperuricemia was associated with a
poor prognosis (Table 4). Hyperuricemia increased the risk ofTable 3. Basal clinical characteristics of progression and nonprogressi
Progression group (n¼26)
Sex, men, n (%) 61.5% (16)
Age 35.58713.58
DM, n (%) 1 (3.8%)
Hypertension, n (%) 11 (42.3%)
Hyperuricemia, n (%) 14 (53.8%)
Systolic BP (mmHg) 131.15716.57
Diastolic BP (mmHg) 83.4677.45
BMI 24.4574.78
Albumin (g/dL) 3.3970.65
BUN (mg/dL) 18.5276.73
Creatinine (mg/dL) 1.3070.66
Initial GFR (ml/min/1.73 m2) 73.44729.92
Uric acid (mg/dL) 6.8571.76
Cholesterol (mg/dL) 155.44791.07
Triglyceride (mg/dL) 210.00761.14
Hypercholesterolemia, n (%) 6 (23.1%)
Hypertriglyceridemia, n (%) 13 (50.0%)
24-h urine protein (mg/day) 315672752
Proteinuria (41.0 g/d), n (%) 19 (73.1%)
Proteinuria (43.5 g/d), n (%) 9 (34.6)
Pathologic grade IV/Vy, n (%) 12 (46.2)
n By Chi-square test.
y The pathologic grading system was determined according to Lee [11].
BMI, body mass index; BUN, blood urea nitrogen; DM, diabetes mellitus; G
Table 2. Hyperuricemia for the risk of GFRo60 ml/min/1.73 m2
Odds ratio (95% conﬁdence interval)
for GFRo60 ml/min/1.73 m2 in
hyperuricemia
Model 1 6.14 (2.69–14.03)
Model 2 6.76 (2.83–16.10)
Model 3 4.20 (1.53–11.52)
Model 1: unadjusted; Model 2: adjusted for age, gender; Model 3:
adjusted for age, gender, body mass index, hypertriglyceridemia, hyperch-
olesterolemia, and proteinuria.
GFR, glomerular ﬁltration rate.IgAN progression by 4.87 (range 1.99–11.92) in the unadjusted
analysis. After adjustment for age, gender, hypertension, hyper-
triglyceridemia, hypercholesterolemia, BMI, and proteinuria,
patients with hyperuricemia still had a signiﬁcantly increased
risk of IgAN progression (mean 4.53, range 1.31–15.66; Table 4).
The renal survival curves differed signiﬁcantly depending
on the presence of hyperuricemia (Fig. 2).
Association between other factors and IgAN progression
Class IV and V renal lesions, hypertension, and proteinuria
were signiﬁcantly associated with a poor prognosis (Table 3).
A signiﬁcant relationship was not found between hyperur-
icemia and proteinuria.Discussion
Hyperuricemia, which is a predictor of coronary heart
disease, stroke, and atherosclerosis, may also have a direct
pathogenic role in the deterioration of renal function
[7–10,12–15]. Many clinical studies have shown signiﬁcant
correlations between serum uric acid and tubular atrophy,
interstitial ﬁbrosis and inﬂammation, proteinuria, and
glomerulosclerosis [7,9,10]. Although the underlying mechan-
isms remain undetermined, hyperuricemia at the time of renalon groups
Nonprogression group (n¼119) P
52.1% (62) 0.5n
34.03713.21 0.6
6 (5.0%) 1.000n
21 (17.6%) 0.009n
23 (19.3%) 0.001n
120.55714.87 0.002
76.60710.31 0.002
23.2073.36 0.1
3.8970.61 o0.001
14.0474.99 o0.001
1.0070.30 o0.001
86.79723.71 0.01
5.3671.61 o0.001
126.99768.64 0.08
178.81751.20 0.007
8 (6.7%) 0.02n
28 (23.5%) 0.01n
122572610 0.001
38 (31.9%) o0.001n
10 (8.4%) 0.001n
4 (3.4%) o0.001n
FR, glomerular ﬁltration rate.
Table 4. Hyperuricemia for the risk of IgAN progression
Odds ratio (95% conﬁdence interval)
for progression in hyperuricemia
Model 1 4.87 (1.99–11.92)
Model 2 4.97 (2.01–12.28)
Model 3 4.53 (1.31–15.66)
Model 1: unadjusted; Model 2: adjusted for age, gender; Model 3:
adjusted for age, gender, body mass index, hypertriglyceridemia, hyperch-
olesterolemia, hyperuricemia, and proteinuria.
Figure 2. Cumulative renal survival curves in the non-hyperurice-
mia and the hyperuricemia groups (Po0.001).
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with normal renal function at the time of biopsy [4].
Numerous studies have assessed the risk factors for progres-
sion of renal insufﬁciency in IgAN. Hypertension, an elevated
serum creatinine concentration, severe proteinuria, older age,
male gender, and the absence of macroscopic hematuria were
found to be independent risk factors [3,24]. Recent studies have
shown that hyperuricemia is also an important risk factor for
IgAN progression, which is related to the central role of
hyperuricemia in tubulointerstitial damage [3–5].
Factors such as volume depletion, alcohol intake, and a high
purine diet may cause hyperuricemia [10,16]. Furthermore, a
decreased GFR may result in decreased uric acid excretion in
the urine, depending on the degree of gastrointestinal excre-
tory compensation, and this may cause hyperuricemia [17,18].
However, whether hyperuricemia increases the risk of renal
progression or is associated with a decrease in GFR is not
entirely clear. Hyperuricemia was an independent risk factor
for IgAN progression in a study of patients with normal renal
function [4]. In this study, subgroup analysis of patients with
normal renal function at diagnosis of IgAN showed that
hyperuricemia has a tendency to increase the risk of IgAN
progression. Furthermore, the presence of hyperuricemia sig-
niﬁcantly increased the risk for progression of IgAN in the
whole patients in the multiple regression analysis.
The presence of hyperuricemia is an independent predictor
for the development of hypertension [1,2], and hypertension
is a risk factor for IgAN progression and virtually all other
renal diseases. At the diagnosis of IgAN, hypertension was
observed in 6% to 49% of patients [3]; in this study, the
frequency of hypertension was 20.7%. Hypertension was more
common in the hyperuricemia group than in the nonhyper-
uricemia group (32% vs. 16.8%, P¼0.027). Multiple logistic
regression analysis showed that hypertension signiﬁcantly
increased the risk of IgAN progression and hyperuricemia.
Proteinuria appears to be an independent clinical risk factor
predictive of a progressive course in patients with IgAN.
Generally, urinary protein excretion 41 g/day is known to
increase the risk of poor renal outcome [3,19–21]. In this study,
37.8% (73/193) of patients had proteinuria Z1 g/day andpatients with hyperuricemia were more likely to have protei-
nuria than those without hyperuricemia (56.0% vs. 31.5%,
respectively; Po0.01). Furthermore, proteinuria was an inde-
pendent risk factor for IgAN progression in the multiple
regression analysis.
The association between the initial uric acid level and the
longitudinal change in proteinuria was evaluated. However,
signiﬁcant associations were not found between hyperurice-
mia and the changes in the amount of proteinuria.
Hyperuricemia has been associated with several compo-
nents of the metabolic syndrome, including hypertension,
glucose intolerance, high BMI, and obesity. Obesity with hyper-
tension or hyperlipidemia may accelerate renal damage [22]
and promote proteinuria in healthy men [23]. Hypertriglycer-
idemia and a high BMI are potential independent risk factors for
IgAN progression. In the present study, a high BMI and
hypertriglyceridemia were common in patients with hyperur-
icemia, and these patients had an increased risk of IgAN
progression in the univariate analysis. However, the multiple
regression analysis did not show a signiﬁcant association.
This study had several limitations. First, the serum uric
acid level was measured on only one occasion, resulting in a
possible underestimation of the strength of its association
with IgAN progression. An average value, determined by
multiple measurements, would yield greater differences in
the frequency of IgAN progression associated with hyperur-
icemia. Second, in addition to a decrease in the GFR, factors
such as volume depletion, alcohol intake, and a high purine
diet are causes of hyperuricemia [10,16]. Unfortunately, this
study did not evaluate these factors. Third, the current results
do not deﬁnitively show that uric acid itself caused the
disease and/or its progression because of the observational
study design.
We conclude that, in addition to various risk factors such
as hypertension, proteinuria, and hyperlipidemia, hyperurice-
mia at the time of IgAN diagnosis is an important and
independent risk factor for IgAN progression.Conﬂict of interest
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